Table 1.
Characteristics of 1,770 Caucasian subjects, Mayo Clinic, MN and Duke University, NC, 1999–2006
| Mayo | Duke | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic* | Level | Cases | Controls | P† | Cases | Controls | P† |
| N | 385 | 462 | 444 | 479 | |||
| Age, y | Mean (S.D.) | 59.9 (13.4) | 60.0 (13.0) | 0.91 | 54.6 (11.3) | 54.8 (12.0) | 0.82 |
| Body mass index‡, kg/m2 | < 23 | 76 (20.5) | 107 (24.8) | 0.03 | 120 (27.8) | 129 (27.6) | 0.54 |
| 23–26 | 88 (23.2) | 121 (28.0) | 106 (24.5) | 117 (25.1) | |||
| 26–29 | 96 (25.9) | 110 (25.5) | 88 (20.4) | 110 (23.6) | |||
| ≥ 29 | 112 (30.3) | 94 (21.8) | 118 (27.3) | 111 (23.8) | |||
| Age at menarche, y | < 12 | 52 (18.2) | 67 (15.8) | 0.47 | 110 (24.8) | 85 (17.7) | 0.05 |
| 12 | 75 (26.3) | 97 (22.9) | 129 (29.1) | 143 (29.9) | |||
| 13 | 78 (27.4) | 124 (29.2) | 106 (23.9) | 139 (29.0) | |||
| ≥ 14 | 80 (28.1) | 136 (32.1) | 98 (22.1) | 112 (23.4) | |||
| Oral contraceptive use, months | Never | 171 (47.6) | 164 (38.6) | <0.001 | 137 (31.4) | 147 (30.9) | 0.65 |
| 1–48 | 94 (26.2) | 90 (21.2) | 133 (30.5) | 134 (28.2) | |||
| ≥ 48 | 94 (26.2) | 171 (40.2) | 166 (38.1) | 194 (40.8) | |||
| Postmenopausal status | Yes | 262 (71.2) | 327 (75.2) | 0.20 | 302 (73.5) | 316 (67.2) | 0.04 |
| Postmenopausal hormone use, months | Never | 231 (63.1) | 243 (58.4) | 0.40 | 151 (35.0) | 278 (59.5) | <0.001 |
| 1–60 | 63 (17.2) | 79 (19.0) | 168 (38.9) | 99 (21.2) | |||
| ≥ 60 | 72 (19.7) | 94 (22.6) | 113 (26.2) | 90 (19.3) | |||
| Parity, n/Age at first birth, y | Nulliparous | 68 (18.2) | 64 (14.8) | 0.07 | 95 (21.4) | 62 (12.9) | 0.01 |
| 1–2/≤ 20 y | 28 (7.5) | 25 (5.8) | 56 (12.6) | 56 (11.7) | |||
| 1–2/>20 y | 102 (27.3) | 128 (29.6) | 171 (38.5) | 212 (44.3) | |||
| ≥ 3/≤ 20 y | 71 (19.0) | 63 (14.5) | 59 (13.3) | 62 (12.9) | |||
| ≥ 3/>20 y | 104 (27.9) | 153 (35.3) | 63 (14.2) | 87 (18.2) | |||
| Family history of ovarian cancer§ | Yes | 50 (13.4) | 32 (7.3) | 0.004 | 33 (7.4) | 20 (4.2) | 0.03 |
| Smoking, pack y | None | 227 (65.2) | 279 (68.0) | 0.42 | 245 (57.4) | 248 (54.0) | 0.60 |
| ≤ 20 | 69 (19.8) | 83 (20.2) | 102 (23.9) | 120 (26.1) | |||
| > 20 | 52 (14.9) | 48 (11.7) | 80 (18.7) | 91 (19.8) | |||
| Education | No diploma | 23 (6.5) | 19 (4.4) | <0.001 | 35 (7.9) | 43 (9.0) | 0.43 |
| High school diploma | 133 (37.7) | 114 (26.1) | 139 (31.3) | 132 (27.6) | |||
| Post high school education | 197 (55.8) | 303 (69.5) | 270 (60.8) | 304 (63.5) | |||
| Multivitamin use|| | Yes | 105 (51.7) | 271 (64.7) | 231 (52.3) | 238 (49.8) | ||
| Tumor histology, cases | Serous | 230 (59.7) | 270 (60.8) | ||||
| Mucinous | 28 (7.3) | 52 (11.7) | |||||
| Endometrioid | 64 (16.6) | 56 (12.6) | |||||
| Clear cell | 22 (5.7) | 29 (6.5) | |||||
| Other | 40 (10.4) | 36 (8.1) | |||||
*
Data are counts (percentage) unless otherwise indicated. Counts do not total to 1,967 subjects due to missing data for some variables.
†
Continuous variables (t-test) and categorical variables (Chi square test).
‡
BMI, body mass index.
§
In first or second degree relative.
||
≥ 4 pills per week during the previous year (Mayo subjects) or ‘regular multivitamin’ use (Duke subjects).